TR200001876T2 - HIV proteaz inhibitörünün bisülfat tuzu. - Google Patents

HIV proteaz inhibitörünün bisülfat tuzu.

Info

Publication number
TR200001876T2
TR200001876T2 TR2000/01876T TR200001876T TR200001876T2 TR 200001876 T2 TR200001876 T2 TR 200001876T2 TR 2000/01876 T TR2000/01876 T TR 2000/01876T TR 200001876 T TR200001876 T TR 200001876T TR 200001876 T2 TR200001876 T2 TR 200001876T2
Authority
TR
Turkey
Prior art keywords
protease inhibitor
hiv protease
bisulfate salt
salt
following formula
Prior art date
Application number
TR2000/01876T
Other languages
English (en)
Inventor
Singh Janak
Pudipeddi Madhusudhan
D. Lindrud Mark
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200001876(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of TR200001876T2 publication Critical patent/TR200001876T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut bulus, asagidaki formüle sahip azapeptit HIV proteaz inhibitör bilesiginin serbest baz formuna oranla beklenmedik sekilde yüksek çözünürlük/bozulma hizina ve oral biyoyararlanima sahip oldugu bulunan kristalin bisülfat tuzunu sunmaktadir:
TR2000/01876T 1998-01-20 1998-12-22 HIV proteaz inhibitörünün bisülfat tuzu. TR200001876T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20

Publications (1)

Publication Number Publication Date
TR200001876T2 true TR200001876T2 (tr) 2000-11-21

Family

ID=22104737

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01876T TR200001876T2 (tr) 1998-01-20 1998-12-22 HIV proteaz inhibitörünün bisülfat tuzu.

Country Status (39)

Country Link
US (1) US6087383A (tr)
EP (1) EP1056722B1 (tr)
JP (2) JP4860037B2 (tr)
KR (1) KR100559283B1 (tr)
CN (1) CN1116282C (tr)
AR (1) AR014417A1 (tr)
AT (1) ATE219057T1 (tr)
AU (1) AU735875B2 (tr)
BG (1) BG64774B1 (tr)
BR (1) BR9814736A (tr)
CA (1) CA2317736C (tr)
CO (1) CO4970820A1 (tr)
CZ (1) CZ293507B6 (tr)
DE (1) DE69806067T2 (tr)
DK (1) DK1056722T3 (tr)
EE (1) EE04434B1 (tr)
EG (1) EG23936A (tr)
ES (1) ES2178300T3 (tr)
GE (1) GEP20033026B (tr)
HK (2) HK1033667A1 (tr)
HU (1) HU227196B1 (tr)
IL (2) IL137384A0 (tr)
LT (1) LT4780B (tr)
LV (1) LV12522B (tr)
MY (1) MY114838A (tr)
NO (1) NO315605B1 (tr)
NZ (1) NZ504417A (tr)
PE (1) PE20000185A1 (tr)
PL (1) PL190744B1 (tr)
PT (1) PT1056722E (tr)
RO (1) RO118869B1 (tr)
RU (1) RU2186070C2 (tr)
SK (1) SK283975B6 (tr)
TR (1) TR200001876T2 (tr)
TW (1) TW531531B (tr)
UA (1) UA59432C2 (tr)
UY (1) UY25345A1 (tr)
WO (1) WO1999036404A1 (tr)
ZA (1) ZA9956B (tr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010733A (es) * 2001-05-22 2004-07-01 Upjohn Co Compuestos de etilamina aza-hidroxilados.
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
ATE398455T1 (de) * 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
US7642049B2 (en) 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
ES2574831T3 (es) * 2006-07-21 2016-06-22 Gilead Sciences, Inc. Inhibidores de la proteasa antivirales
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
BRPI0823520A2 (pt) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
EP2178512B1 (en) * 2007-06-22 2011-03-09 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
PT2170292E (pt) * 2007-06-22 2014-03-06 Bristol Myers Squibb Holdings Ireland Composições de comprimido contendo atazanavir
SI2178513T1 (sl) * 2007-06-22 2011-05-31 Bristol Myers Squibb Co Tabletni sestavki vsebujoäśi atazanavir
DE602008005316D1 (de) * 2007-06-22 2011-04-14 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
JP5547066B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療用組成物およびその使用
EP2288593A1 (en) * 2008-05-08 2011-03-02 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
EP2376452A4 (en) 2009-01-12 2012-08-29 Hetero Research Foundation NEW SULFATE POLYMORPH OF ATAZANAVIR
JP2012528160A (ja) 2009-05-27 2012-11-12 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖプロテアーゼ阻害薬
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
PL2493312T3 (pl) 2009-10-26 2022-01-03 Merck Sharp & Dohme Corp. Kompozycje farmaceutyczne w postaci ciała stałego zawierające inhibitor integrazy
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
WO2011107843A2 (en) 2010-03-01 2011-09-09 Lupin Limited Process for the preparation of atazanavir sulfate substantially free of diastereomers
EP2555757B1 (en) 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
EP2621472A1 (en) 2010-09-28 2013-08-07 Ratiopharm GmbH Dry processing of atazanavir
US20140343290A1 (en) 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
EP2888230A4 (en) 2012-08-24 2017-07-19 Laurus Labs Private Limited Improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
US9890121B2 (en) 2013-02-12 2018-02-13 Cipla Limited Process for preparing atazanavir sulphate
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
US6087383A (en) 2000-07-11
BR9814736A (pt) 2000-10-24
NZ504417A (en) 2001-09-28
EP1056722B1 (en) 2002-06-12
WO1999036404A1 (en) 1999-07-22
CN1116282C (zh) 2003-07-30
KR20010034221A (ko) 2001-04-25
DE69806067D1 (de) 2002-07-18
UY25345A1 (es) 2000-12-29
PE20000185A1 (es) 2000-05-14
AU735875B2 (en) 2001-07-19
HU227196B1 (en) 2010-10-28
JP2002509136A (ja) 2002-03-26
DE69806067T2 (de) 2003-01-23
CZ293507B6 (cs) 2004-05-12
EP1056722A1 (en) 2000-12-06
GEP20033026B (en) 2003-07-25
PT1056722E (pt) 2002-09-30
IL137384A (en) 2006-08-01
HK1033667A1 (en) 2001-09-14
ATE219057T1 (de) 2002-06-15
UA59432C2 (uk) 2003-09-15
NO20003692L (no) 2000-07-19
HUP0101389A3 (en) 2003-07-28
CA2317736C (en) 2004-11-02
JP4860037B2 (ja) 2012-01-25
ZA9956B (en) 2000-07-05
NO20003692D0 (no) 2000-07-19
CO4970820A1 (es) 2000-11-07
AU2010199A (en) 1999-08-02
CA2317736A1 (en) 1999-07-22
LT2000067A (en) 2000-11-27
CZ20002564A3 (cs) 2000-10-11
LV12522A (en) 2000-08-20
BG104618A (en) 2001-02-28
EE04434B1 (et) 2005-02-15
IL137384A0 (en) 2001-07-24
JP2009102357A (ja) 2009-05-14
SK10622000A3 (sk) 2001-02-12
MY114838A (en) 2003-01-31
ES2178300T3 (es) 2002-12-16
KR100559283B1 (ko) 2006-03-15
HUP0101389A2 (hu) 2001-08-28
NO315605B1 (no) 2003-09-29
EG23936A (en) 2008-01-14
SK283975B6 (sk) 2004-06-08
HK1033458A1 (en) 2001-08-31
PL190744B1 (pl) 2006-01-31
EP1056722A4 (en) 2001-01-10
RU2186070C2 (ru) 2002-07-27
CN1283188A (zh) 2001-02-07
PL342019A1 (en) 2001-05-07
BG64774B1 (bg) 2006-03-31
AR014417A1 (es) 2001-02-28
TW531531B (en) 2003-05-11
LT4780B (lt) 2001-04-25
EE200000798A (et) 2002-06-17
RO118869B1 (ro) 2003-12-30
DK1056722T3 (da) 2002-09-30
LV12522B (en) 2000-10-20

Similar Documents

Publication Publication Date Title
TR200001876T2 (tr) HIV proteaz inhibitörünün bisülfat tuzu.
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
DK0931788T3 (da) Metalloproteasehæmmere
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
DK1385515T3 (da) Spiropyrazole forbindelser
DK1140918T3 (da) Thrombininhibitorer
YU5503A (sh) Nesteroidni supresori zapaljenja
ATE292634T1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ATE235462T1 (de) Metalloproteinase-inhibitoren
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
SE0103710D0 (sv) Compounds
CY1107635T1 (el) Μεθοδος για την παρασκευη σιταλοπραμης
NO20015892L (no) Inhibitorer av metallproteinaser
BG107003A (en) Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
IT1320107B1 (it) Procedimento per la preparazione di derivati tassanici.
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
DE60101784D1 (de) Synthese von wasserlöslischem 9-dihydroplacitaxel derivate aus 9-dihydro-13-acetylbacchatin iii
NO20024679D0 (no) Krystallinsk farmasöytikum
BR0009795A (pt) Processo para a ppeparação de um composto da fórmula (i), e, composto
ECSP982595A (es) Compuestos farmaceuticos
UY26778A1 (es) Derivados de ácido heteroarilalcanoico.
ATE261962T1 (de) Benzonaphtyridin-1,8 derivate
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων